白细胞介素8在口腔鳞癌上皮-间充质转化中的研究进展

doi:10.19438/j.cjoms.2020.06.018

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (6): 563-566.doi: 10.19438/j.cjoms.2020.06.018

白细胞介素8在口腔鳞癌上皮-间充质转化中的研究进展

徐桥石, 杨溪, 马海龙, 常涵月, 张陈平

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2019-07-24 修回日期:2020-01-09 发布日期:2020-12-31
通讯作者: 张陈平,E-mail:zhang.chenping@hotmail.com
作者简介:徐桥石(1992-),男,博士,E-mail:xqsgarfield@126.com

Progress on interleukin-8 in epithelial-mesenchymal transition of oral squamous cell carcinoma

XU Qiao-shi, YANG Xi, MA Hai-long, CHANG Han-yue, ZHANG Chen-ping

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China

Received:2019-07-24 Revised:2020-01-09 Published:2020-12-31

摘要/Abstract

摘要： 白细胞介素8是CXC趋化因子家族的一员,除具有趋化免疫细胞的作用外,对于肿瘤组织的发生、发展更是有着显著影响。本文简述白细胞介素8的生物学特点,分析其促进口腔鳞癌上皮-间充质转化行为的现象和原因,目前白细胞介素8在该领域的主要研究进展,并提出未来的研究方向。

关键词: 白细胞介素8, 口腔鳞癌, 上皮-间充质转化

Abstract: Interleukin-8 IL-8 is a chemokine belonging to CXC subgroup, it plays a critical role in tumor progress as well as attracting immune cell. In this review, we descripted the biological characteristics of IL-8, analyzed its promoting function for epithelial-mesenchymal transition in oral squamous cell carcinoma, and summarized the progress of current studies. Based on the results of existing researches, the outlook for future study about IL-8 was proposed. ;

Key words: Interleukin 8, Oral squamous cell carcinoma, Epithelial-mesenchymal transition

中图分类号:

R739.8

徐桥石, 杨溪, 马海龙, 常涵月, 张陈平. 白细胞介素8在口腔鳞癌上皮-间充质转化中的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(6): 563-566.

XU Qiao-shi, YANG Xi, MA Hai-long, CHANG Han-yue, ZHANG Chen-ping. Progress on interleukin-8 in epithelial-mesenchymal transition of oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2020, 18(6): 563-566.

参考文献

[1] Safiri S, Sullman M, Ashrafi-Asgarabad A.Prognostic value of pathologic grade for patients with oral squamous cell carcinoma[J]. Oral Dis, 2018, 24(5): 868-876.
[2] 刘墨, 李劲松, 阮毅, 等. miR-181a抑制舌鳞癌细胞上皮-间充质转化及化疗耐药机制的研究[J]. 中国口腔颌面外科杂志, 2018, 16(4): 289-295.
[3] Puram SV, Tirosh I, Parikh AS, et al.Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer[J]. Cell, 2017, 171(7): 1611-1624.
[4] Petruzzi MN, Cherubini K, Salum FG, et al.Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge[J]. Diagn Pathol, 2017, 12(1): 32-38.
[5] Nagarsheth N, Wicha MS, Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J]. Nat Rev Immunol, 2017, 17(9): 559-572.
[6] Lippitz BE.Cytokine patterns in patients with cancer: a systematic review[J]. Lancet Oncol, 2013, 14(6): e218-e228.
[7] Yoshimura T, Matsushima K, Oppenheim JJ, et al.Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1(IL 1)[J]. J Immunol, 1987, 139(3): 788-793.
[8] 杨蒙, 刘晓斌. 白细胞介素8与肿瘤的研究进展[J]. 中国医药导报, 2016, 13(26): 33-37,47.
[9] 肖著军, 许岸高. 白细胞介素8与大肠癌关系的研究进展[J]. 广东医学, 2012, 33(22): 3493-3495.
[10] Waugh DJ, Wilson C.The interleukin-8 pathway in cancer[J]. Clin Cancer Res, 2008, 14(21): 6735-6741.
[11] Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, et al.Interleukin-8 in cancer pathogenesis, treatment and follow-up[J]. Cancer Treat Rev, 2017, 60: 24-31.
[12] Chan LP, Wang LF, Chiang FY, et al.IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway[J]. Oncotarget, 2016, 7(38): 61820-61831.
[13] Christofakis EP, Miyazaki H, Rubink DS, et al.Roles of CXCL8 in squamous cell carcinoma proliferation and migration[J]. Oral Oncol, 2008, 44(10): 920-926.
[14] Ha H, Debnath B, Neamati N.Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases[J]. Theranostics, 2017, 7(6): 1543-1588.
[15] 姚瑶, 王琳琳. 白细胞介素8研究进展. 实用儿科临床杂志[J]. 2009, 24(10): 789-792.
[16] Meniailo ME, Malashchenko VV, Shmarov VA, et al.Direct effects of interleukin-8 on growth and functional activity of T lymphocytes[J]. Int Immunopharmacol, 2017, 50: 178-185.
[17] Montaldo E, Vitale C, Cottalasso F, et al.Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor[J]. Blood, 2012, 119(17): 3987-3996.
[18] 司马秀山, 李荣哲, 张昕. 白细胞介素8基因在口腔鳞癌中的表达及意义[J]. 口腔颌面外科杂志, 2013, 23(2): 95-97.
[19] 冯红超, 彭玉峰, 宋宇峰. 口腔鳞癌中白细胞介素8的表达及临床意义[J]. 贵阳医学院学报, 2008, 33(5), 446-448,452.
[20] Miyamoto M, Shimizu Y, Okada K, et al.Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells[J]. Cancer Immunol Immunother, 1998, 47(1): 47-57.
[21] Sunaga N, Imai H, Shimizu K, et al.Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer[J]. Int J Cancer, 2012, 130(8): 1733-1744.
[22] Huang W, Chen Z, Zhang L, et al.Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice[J]. Gastroenterology, 2015, 149(4): 1053-1067.
[23] Li A, Dubey S, Varney ML, et al.IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis[J]. J Immunol, 2003, 170(6): 3369-3376.
[24] Cho BH, Jung YH, Kim DJ, et al.Acetylshikonin suppresses invasion of Porphyromonas gingivalis infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis[J]. Mol Med Rep, 2018, 17(2): 2327-2334.
[25] Knall C, Worthen GS, Johnson GL.Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases[J]. Proc Natl Acad Sci, 1997, 94(7): 3052-3057.
[26] Cheng GZ, Park S, Shu S, et al.Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery[J]. Curr Cancer Drug Targets, 2008, 8(1): 2-6.
[27] Zhang Y, Wang L, Zhang M, et al.Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway[J]. J Cell Physiol, 2012, 227(1): 35-43.
[28] 张青云, 傅俊江, 陈汉春. 上皮-间质转化介导肿瘤转移的分子机制[J]. 生命科学研究, 2018, 22(6): 503-510.
[29] New J, Arnold L, Ananth M, et al.Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target[J]. Cancer Res, 2017, 77(23): 6679-6691.
[30] Gyanchandani R, Sano D, Ortega Alves MV, et al.Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(8): 761-770.
[31] Peng HY, Jiang SS, Hsiao JR, et al.IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma[J]. Mol Oncol, 2016, 10(6): 895-909.
[32] Ha NH, Park DG, Woo BH, et al.Porphyromonas gingivalis increases the invasiveness of oral cancer cells by upregulating IL-8 and MMPs[J]. Cytokine, 2016, 86: 64-72.
[33] Liu Q, Li A, Tian Y, et al.The CXCL8-CXCR1/2 pathways in cancer[J]. Cytokine Growth Factor Rev, 2016, 31: 61-71.

白细胞介素8在口腔鳞癌上皮-间充质转化中的研究进展

Progress on interleukin-8 in epithelial-mesenchymal transition of oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[3]	李华盛, 周迪, 韩楠男, 严明, 阮敏. 石蒜碱通过降解SCAP蛋白抑制口腔鳞癌细胞增殖与侵袭的实验研究[J]. 中国口腔颌面外科杂志, 2024, 22(1): 29-35.
[4]	刘恒, 李永頔, 尹鑫海, 段晓峰. 铁蛋白重链1在头颈鳞癌中的表达及对口腔鳞癌增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(6): 529-537.
[5]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[6]	朱方兴, 周知航, 琚梧桐, 谈亦然, 刘莹, 钟来平, 赵铜超. 基于基线期dNLR水平对局部晚期口腔鳞癌患者生存的预后预测—10年临床回顾[J]. 中国口腔颌面外科杂志, 2023, 21(6): 566-571.
[7]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[8]	吴朱昊, 张兴伟, 孙亚威, 李子慧, 陈欣, 蒲玉梅, 胡勤刚, 董迎春, 孙国文. ICG荧光导航技术在晚期口腔鳞癌救治性手术中的应用[J]. 中国口腔颌面外科杂志, 2023, 21(3): 248-252.
[9]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[10]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[11]	许刚, 宋其义, 蒋卫东, 刘景秀. 水通道蛋白3在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 478-482.
[12]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.
[13]	张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.
[14]	魏东亮, 李智, 鞠侯雨, 吴云腾, 郭伟, 任国欣. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
[15]	孙大为, 张云, 朱勇. shRNA干扰Rce1基因表达对口腔鳞癌细胞放射敏感性的影响[J]. 中国口腔颌面外科杂志, 2022, 20(2): 123-128.